Daiichi Korea's sales and profits declined.

Published: 2005-06-14 06:57:00

Updated: 2005-06-14 06:57:00

Daiichi Korea reported the 15th fiscal year (April 1, 2004 to Mar. 31, 2005) financial statement covering 11.1 billion won of sales (3.24% up from the previous year period), 1,376 million won of operating income (36.76% down), 1,381 million won of ordinary income (900 million won less from the pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK